Guna

GUNA is a Sanskrit term which means "all life energies of living beings". A parallel can be drawn between the essence of this ancient word and GUNA's international reputation for leading edge science and medical advancement. A hallmark of GUNA's commitment to scientific innovation is collaboration in both Research and Development and medical education within the Academic community in various well-known Universities, first of all the State University of Milan (Università degli Studi di Milano). This cornerstone of GUNA's vision ensures that the company is and will be on the forefront of integrative medicine - thereby providing the most advanced medical treatment concepts and products available today. GUNA (GUNA S.p.a.) is the most important pharmaceutical company in Italy in the field of biological medicine with a turnover of over 50 Million Euro. The company was founded in 1983 and its headquarter is located in Milan, Via Palmanova 71. In 1989 the Italian Health Ministry* authorized GUNA to produce medicines. Since then, GUNA has developed an important production department: the main manufacturing facility (Via Palmanova 69) has a surface of about 60.000 sq. mt. and is considered among the most modern pharmaceutical laboratory in the world. GUNA has two production facilities in Milan: GUNA Laboratory - Via Palmanova 69, for the production of low dose medicines, medical devices and cosmetics. GUNA Laboratory - Via Vanvitelli 6, for the production of Bach Flowers. GUNA employs more than 250 people, working in the departments of production, logistic, administration, marketing and medical-scientific information. The company's related activities include an intensive program of continuing medical education for physicians (seminars and e-learning courses) and the publication of a specialist journal in English, "PHYSIOLOGICAL REGULATING MEDICINE". GUNA also supports several Associations operating to provide training for physicians and pharmacists. GUNA promotes numerous clinical and basic research conducted according to state-of-the-art scientific standards (e.g. on allergic asthma, published in "Pulmonary Pharmacology and Therapeutics") and allocates a sizable part of its budget to research and development. GUNA's products are distributed in over 40 Countries. Due to the increase in demand from the USA for innovative and modern health solutions, GUNA has expanded to North America. GUNA Inc., the US subsidiary - located in Whitehall (PA) - opened its doors in 2006 to provide cutting edge solutions via the GUNA Method and GUNA's products. Today GUNA has more than 70 products FDA listed.